Jeroen Geurtsen, Joachim Doua, Luis Martinez-Martinez, Patricia Ibarra de Palacios, Jeff Powis, Matthew Sims, Peter Hermans, Olivier Barraud, Philippe Lanotte, Joshua Thaden, Oscar Go, Bart Spiessens, Darren Abbanat, Florian Wagenlehner, Tetsuya Matsumoto, Marc Bonten, Michal Sarnecki, Jan Poolman
{"title":"一项对三级医院住院患者侵袭性大肠杆菌o血清型患病率的全球回顾性研究","authors":"Jeroen Geurtsen, Joachim Doua, Luis Martinez-Martinez, Patricia Ibarra de Palacios, Jeff Powis, Matthew Sims, Peter Hermans, Olivier Barraud, Philippe Lanotte, Joshua Thaden, Oscar Go, Bart Spiessens, Darren Abbanat, Florian Wagenlehner, Tetsuya Matsumoto, Marc Bonten, Michal Sarnecki, Jan Poolman","doi":"10.1017/S0950268825100344","DOIUrl":null,"url":null,"abstract":"<p><p>Invasive <i>Escherichia coli</i> disease (IED) is associated with high hospitalization and mortality rates, particularly among adults aged ≥60 years. O-antigens are virulence factors required for <i>E. coli</i> survival. To inform EXPEC9V development, a novel glycoconjugate vaccine targeting <i>E. coli</i> O-antigens that is no longer in active clinical development, this retrospective observational study describes O-serotype prevalence among <i>E. coli</i> isolates from IED patients. Eligible patients were identified from medical record databases (9 January 2018-8 November 2019) across 17 tertiary care hospitals in Europe, North America, and Asia. To estimate vaccine serotype coverage of EXPEC9V, <i>E. coli</i> isolates were O-serotyped using whole-genome sequencing and agglutination. Antimicrobial susceptibility testing was also performed. Nine hundred and two patients were enrolled, of whom 690 (76.5%) were aged ≥60 years. Common serotypes were O25, O2, O6, O1, O15, O75, O16, O4, and O18, with O25 being the most reported (17.3%). In patients aged ≥60 years, 422/637 <i>E. coli</i> isolates were EXPEC9V O-serotypes. EXPEC9V O-serotype prevalence did not substantially differ when stratified according to sex, presence of a positive blood culture, sepsis, fatality, or multidrug resistance. Consistent with previous studies, serotype O25 was most prevalent and associated with ~20% of cases. An EXPEC9V vaccine serotype coverage of 66.2% was observed for IED patients aged ≥60 years.</p>","PeriodicalId":11721,"journal":{"name":"Epidemiology and Infection","volume":" ","pages":"e109"},"PeriodicalIF":2.2000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A retrospective global study of the prevalence of O-serotypes of invasive <i>Escherichia coli</i> disease in patients admitted to tertiary care hospitals.\",\"authors\":\"Jeroen Geurtsen, Joachim Doua, Luis Martinez-Martinez, Patricia Ibarra de Palacios, Jeff Powis, Matthew Sims, Peter Hermans, Olivier Barraud, Philippe Lanotte, Joshua Thaden, Oscar Go, Bart Spiessens, Darren Abbanat, Florian Wagenlehner, Tetsuya Matsumoto, Marc Bonten, Michal Sarnecki, Jan Poolman\",\"doi\":\"10.1017/S0950268825100344\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Invasive <i>Escherichia coli</i> disease (IED) is associated with high hospitalization and mortality rates, particularly among adults aged ≥60 years. O-antigens are virulence factors required for <i>E. coli</i> survival. To inform EXPEC9V development, a novel glycoconjugate vaccine targeting <i>E. coli</i> O-antigens that is no longer in active clinical development, this retrospective observational study describes O-serotype prevalence among <i>E. coli</i> isolates from IED patients. Eligible patients were identified from medical record databases (9 January 2018-8 November 2019) across 17 tertiary care hospitals in Europe, North America, and Asia. To estimate vaccine serotype coverage of EXPEC9V, <i>E. coli</i> isolates were O-serotyped using whole-genome sequencing and agglutination. Antimicrobial susceptibility testing was also performed. Nine hundred and two patients were enrolled, of whom 690 (76.5%) were aged ≥60 years. Common serotypes were O25, O2, O6, O1, O15, O75, O16, O4, and O18, with O25 being the most reported (17.3%). In patients aged ≥60 years, 422/637 <i>E. coli</i> isolates were EXPEC9V O-serotypes. EXPEC9V O-serotype prevalence did not substantially differ when stratified according to sex, presence of a positive blood culture, sepsis, fatality, or multidrug resistance. Consistent with previous studies, serotype O25 was most prevalent and associated with ~20% of cases. An EXPEC9V vaccine serotype coverage of 66.2% was observed for IED patients aged ≥60 years.</p>\",\"PeriodicalId\":11721,\"journal\":{\"name\":\"Epidemiology and Infection\",\"volume\":\" \",\"pages\":\"e109\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-09-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Epidemiology and Infection\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1017/S0950268825100344\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epidemiology and Infection","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/S0950268825100344","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
A retrospective global study of the prevalence of O-serotypes of invasive Escherichia coli disease in patients admitted to tertiary care hospitals.
Invasive Escherichia coli disease (IED) is associated with high hospitalization and mortality rates, particularly among adults aged ≥60 years. O-antigens are virulence factors required for E. coli survival. To inform EXPEC9V development, a novel glycoconjugate vaccine targeting E. coli O-antigens that is no longer in active clinical development, this retrospective observational study describes O-serotype prevalence among E. coli isolates from IED patients. Eligible patients were identified from medical record databases (9 January 2018-8 November 2019) across 17 tertiary care hospitals in Europe, North America, and Asia. To estimate vaccine serotype coverage of EXPEC9V, E. coli isolates were O-serotyped using whole-genome sequencing and agglutination. Antimicrobial susceptibility testing was also performed. Nine hundred and two patients were enrolled, of whom 690 (76.5%) were aged ≥60 years. Common serotypes were O25, O2, O6, O1, O15, O75, O16, O4, and O18, with O25 being the most reported (17.3%). In patients aged ≥60 years, 422/637 E. coli isolates were EXPEC9V O-serotypes. EXPEC9V O-serotype prevalence did not substantially differ when stratified according to sex, presence of a positive blood culture, sepsis, fatality, or multidrug resistance. Consistent with previous studies, serotype O25 was most prevalent and associated with ~20% of cases. An EXPEC9V vaccine serotype coverage of 66.2% was observed for IED patients aged ≥60 years.
期刊介绍:
Epidemiology & Infection publishes original reports and reviews on all aspects of infection in humans and animals. Particular emphasis is given to the epidemiology, prevention and control of infectious diseases. The scope covers the zoonoses, outbreaks, food hygiene, vaccine studies, statistics and the clinical, social and public-health aspects of infectious disease, as well as some tropical infections. It has become the key international periodical in which to find the latest reports on recently discovered infections and new technology. For those concerned with policy and planning for the control of infections, the papers on mathematical modelling of epidemics caused by historical, current and emergent infections are of particular value.